Indoco Remedies has announced the final approval of the Company’s Abbreviated New Drug Application (ANDA) for Lacosamide Oral Solution USP, 10 mg/mL, to market a generic equivalent to the reference listed drug (RLD), Vimpat Oral Solution, 10 mg/mL, of UCB, Inc. (UCB), from USFDA. This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI Listing Regulations. It has enclosed press release in this regard.
The above information is a part of company’s filings submitted to BSE.
